Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 9/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3865230 | 1.00 | EGFR (0.46) | EGFRALOX5NPC1NCOA1NCOA3 | |
| SCHEMBL3866428 | 0.90 | CISD1 (0.41) | EGFRALOX5ALDH1A1MAPTHTT | |
| SCHEMBL3862770 | 0.90 | CISD1 (0.41) | EGFRALOX5ALDH1A1MAPTHTT | |
| SCHEMBL3861867 | 0.82 | MEN1 (0.43) | ALOX5ALDH1A1MAPTHTTMEN1 | |
| SCHEMBL3861872 | 0.82 | MEN1 (0.43) | ALOX5ALDH1A1MAPTHTTMEN1 | |
| SCHEMBL5088271 | 0.76 | PIK3CD (0.44) | ALOX5MEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL4157222 | 0.75 | CISD1 (0.41) | EGFRALOX5HTTMEN1KMT2A | |
| SCHEMBL3874063 | 0.75 | CLK1 (0.35) | EGFRALOX5NPC1MAPTHTT | |
| SCHEMBL3864238 | 0.75 | CLK1 (0.35) | EGFRALOX5NPC1MAPTHTT | |
| SCHEMBL4157218 | 0.75 | CISD1 (0.41) | EGFRALOX5HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501428-B2 | e.g. 2-(1-hydroxymethyl-2-phenyl-ethylamino)-5-[1-quinazolin-6-yl-methylidene]-thiazol-4-one; cyclin-dependent kinases (CDKs)/serine-threonine protein kinases inhibitor; antiproliferative, anticarcinogenic, antitumor agent | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | claimed |
| EP-1802614-A1 | QUINAZOLINYLMETHYLENETHIAZOLINONES AS CDK1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | claimed |
| WO-2006040050-A1 | QUINAZOLINYLMETHYLENE THIAZOLINONES AS CDK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | claimed |
| US-20060084804-A1 | Quinazoline thiazolinones | CHEN LI | 2006-04-20 | — | — | US | claimed |
| US-7501428-B2 | e.g. 2-(1-hydroxymethyl-2-phenyl-ethylamino)-5-[1-quinazolin-6-yl-methylidene]-thiazol-4-one; cyclin-dependent kinases (CDKs)/serine-threonine protein kinases inhibitor; antiproliferative, anticarcinogenic, antitumor agent | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501428-B2 | e.g. 2-(1-hydroxymethyl-2-phenyl-ethylamino)-5-[1-quinazolin-6-yl-methylidene]-thiazol-4-one; cyclin-dependent kinases (CDKs)/serine-threonine protein kinases inhibitor; antiproliferative, anticarcinogenic, antitumor agent | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501428-B2 | e.g. 2-(1-hydroxymethyl-2-phenyl-ethylamino)-5-[1-quinazolin-6-yl-methylidene]-thiazol-4-one; cyclin-dependent kinases (CDKs)/serine-threonine protein kinases inhibitor; antiproliferative, anticarcinogenic, antitumor agent | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1802614-A1 | QUINAZOLINYLMETHYLENETHIAZOLINONES AS CDK1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040050-A1 | QUINAZOLINYLMETHYLENE THIAZOLINONES AS CDK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| US-20060084804-A1 | Quinazoline thiazolinones | CHEN LI | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084804-A1 | Quinazoline thiazolinones | CDK1, CDK14, CDK18 | EGFR 1674/4885ALOX5 4757/4885NPC1 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.